NYSE:LLYPharmaceuticals
Lilly’s China Bet and U.S. Access Push Could Be A Game Changer For Eli Lilly (LLY)
In early March 2026, Eli Lilly announced a US$3.00 billion, decade-long expansion in China centered on local production and supply for its oral obesity pill orforglipron, while simultaneously rolling out its new Employer Connect platform and Zepbound KwikPen to broaden access to obesity treatments in the U.S.
Together, this China build-out and employer-focused access model underscore how Lilly is trying to anchor obesity care across both global manufacturing and U.S. benefits design.
We’ll...